Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Study Details
Study Description
Brief Summary
The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients. A drug response predictor (DRP®) biomarker in prostate cancer patients will identify patients likely to respond to and benefit from treatment with Irofulven.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Irofulven + Prednisolone 10mg Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle. Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone. |
Drug: Irofulven
Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.
Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone.
Combination Product: Prednisolone 10 mg
Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.
Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone.
|
Outcome Measures
Primary Outcome Measures
- Anti-tumor effect of Irofulven with prednisolone [one year]
Objective response rate defined as complete response, partial response or stable disease > 9 weeks according to RECIST 1.1 for patients with measurable disease and defined as stable disease > 9 weeks according to Prostate Cancer Working Group 3 (PCWG3) for bone metastases
Secondary Outcome Measures
- Duration of response (DOR) [one year]
Time from documentation of tumor response to disease progression
- Radiologic progression free survival (rPFS) [one year]
rPFS defined as ≥ two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory scan, ≥ two new confirmed lesions on any scan ≥ 9 weeks after enrolment, and/or progression in nodes or viscera on cross-sectional imaging, or death.
- Overall survival [one year]
Time from enrolment until death from any cause.
- Prostate Specific Antigen (PSA) response [one year]
≥ 50% decline in PSA compared to baseline in all patients according to PCWG3
- PSA response [one year]
≥ 90% decline in PSA compared to baseline in all patients according to PCWG3
- Time to PSA progression [one year]
PSA progression defined in accordance with PCWG3.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Have a histologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate (carcinomas with pure small-cell histology or pure high grade neuroendocrine histology are excluded; neuroendocrine differentiation is allowed)
-
Surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL. For patients currently being treated with luteinizing hormone-releasing hormone (LHRH) agonists, i.e., patients who have not undergone an orchiectomy, therapy must be continued throughout the study
-
Have evidence of disease progression after prior therapy for mCRPC:
-
Disease progression after treatment with at least 1 but no more than 2 prior next-generation AR-targeted therapies (abiraterone acetate, enzalutamide, or investigational AR-targeted agent) for metastatic prostate cancer (treatment with the older anti-androgen therapies such as bicalutamide, flutamide, and nilutamide are not counted toward this limit), AND
-
Disease progression after treatment with docetaxel for metastatic prostate cancer. Prior Docetaxel therapy administered for hormone-sensitive disease is permitted and is not counted toward this limit
-
Disease progression after initiation of most recent therapy is based on any of the following criteria:
-
Rise in PSA: a minimum of 2 consecutive rising levels, with an interval of ≥ 1 week between each determination. The most recent screening measurement must have been ≥ 1 ng/mL
-
Transaxial imaging: new or progressive soft tissue masses on CT or MRI scans as defined by RECIST 1.1
-
Radionuclide bone scan: at least 2 new metastatic lesions
-
Signed informed consent obtained prior to initiation of any study-specific procedures or treatment.
-
Age ≥ 18 years
-
Life expectancy ≥ 3 months
-
Performance status 0 - 1
-
Have participated in the Irofulven screening protocol in which the Drug Response Predictor (DRP) outcome is measured as being in the upper limit of response (defined as being in the top 20%). Scaling can be modified depending on the clinical outcome.
-
Adequate organ functions
-
Hematological: absolute neutrophil count (ANC) >1.5 x 10E9/L, platelet count >100 x 10E9/L, hemoglobin ≥ 6.2 mmol/L
-
Hepatic: Bilirubin within normal range, aspartate transaminase (AST) and alanine transaminase (ALT) ≥ 2.5 upper normal limit (UNL), albumin > 25 g/L
-
Renal: creatinine clearance ≥ 30 mL/min (calculated according to the Cockcroft and Gault method)
-
Recovered to grade 0 or 1 from any toxic effects of prior chemotherapy, radiotherapy
Exclusion Criteria:
-
Prior external beam radiation therapy to >25% of the bone marrow
-
Contraindication to the use of prednisolone (e.g. uncontrolled diabetes mellitus)
-
Prior treatment with Irofulven.
-
Ongoing treatment with a corticosteroid at a prednisolone-equivalent dose > 10 mg/day
-
More than 1 prior treatment with either isotopes Sm or Sr, or radioisotope treatment or treatment with bisphosphonate agents or antibody treatment i.e., denosumab within 2 months prior to initiation of treatment with investigational Medicinal Product (IMP). Pre-existing treatment with bisphosphonate agents or denosumab is to be continued during the study
-
Initiation of treatment with bisphosphonate agents or antibody treatment i.e., denosumab, within 4 weeks of study start. Pre-existing treatment with bisphosphonate agents or denosumab is to be continued during the study
-
Treatment with coumarin derivatives and/or phenytoin most be discontinued and coagulation parameters most be within the normal range before treatment with Irofulven
-
History of significant gastric or small bowel resection, malabsorption syndrome, or other lack of integrity of the upper gastrointestinal tract that may prevent compliance with oral drug administration
-
Presence of any serious concomitant systemic disorders and/or psychiatric condition incompatible with the study (at the investigators discretion)
-
History of retinopathy
-
Presence of any active infection (at the investigators discretion).
-
Central Nervous System Disease (CNS) disease including epilepsy or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rigshospitalet, Dept. Of Oncology | Copenhagen | Denmark | 2100 |
Sponsors and Collaborators
- Allarity Therapeutics
- Smerud Medical Research International AS
- Lantern Pharma Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SMR-3165
- 2017-003549-72